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Abstract
Background: Krüppel-like factors (KLFs) are critical regulators of biological and physiological systems and have
been extensively studied for their roles in cell proliferation, differentiation and survival in the context of cancer.
Among the KLFs, KLF4 is highly expressed in human breast cancers and plays an oncogenic role. The present study
examined the expression of KLF4 and assessed its significance in canine mammary carcinoma.
Results: Immunohistochemistry was employed to investigate the expression of KLF4 in 142 cases of canine
mammary tumor. 75 of the 142 (52.8%) cases were histologically confirmed as mammary carcinoma. Quantification
of immunohistochemistry was carried out using Quick score which multiply the staining intensity by the
percentage of positive cells. High KLF4 expression was identified in 44 of the 75 (59%) dogs with mammary
carcinoma and none in the benign cases. High KLF4 expression occurred only in the tumor cells and not the
adjacent normal cells in mammary carcinoma (P < 0.001). Moreover, the high expression level of KLF4 expression
was statistically associated with poor grade, late stage, histological subtypes of simple and complex carcinoma, and
shorter 24-month survival. The Kaplan-Meier survival analysis also indicated that dogs with high nuclear KLF4
expression had a significantly shorter survival than those with low/moderate KLF4 expression (P = 0.011).
Conclusions: KLF4 is highly and frequently expressed in canine mammary carcinoma and correlates with a more
aggressive phenotype.
Background
Canine mammary tumors are the most common tumor
in female dogs. The spontaneous, naturally occurring
canine mammary tumors share many features with
human breast cancer such as the predominant malignant
histological type being adenocarcinoma [1-3] and the
expression of estrogen and progesterone receptors (ER/
PR), and epidermal growth factor receptor 2 (HER2) in
subsets of canine mammary carcinoma [4-7]. It has been
suggested that canine mammary carcinomas may be a
suitable natural model for the comparative study of
human breast cancer [4,5,7-9].
The Krüppel-like factor (KLF) family proteins are
transcription factors that play important roles in a wide
range of cellular processes, including embryogenesis,
proliferation, differentiation, migration, inflammation
and tumorigenesis [10-13].
The KLF family consists of 17 different members in
which many have been identified as potentially novel
oncogenes or tumor suppressors [13,14]. Human KLF4
was first identified using a DNA probe containing
the zinc finger region of human erythroid Krüppel-like
factor from human umbilical vein endothelial cell cDNA
library [15]. The biological effects of KLF4 seem to
depend on cancer type rather than unique. KLF4 tran-
scription factor can function as a tumor suppressor and
is down-regulated in various human cancer types such
as gastric and colorectal cancer [16,17]. On the other
hand, high level and oncogenic role of KLF4 were also
reported in human breast cancer and oral squamous
carcinoma [18,19]. This study investigated the presence
of KLF4 and established their clinical significance in
canine mammary carcinoma.
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One hundred forty-two dogs (43 Maltese, 11 Yorkshire
terriers, 11 Shih-Tzus, 9 Pomeranians, 10 Cocker spaniels,
2F r e n c hs p a n i e l s ,2B i c h o nF r i s é ,7p o o d l e s ,2G e r m a n
shepherd dogs, 1 Shiba, 3 Beagles, 1 Labrador Retriever,
1 Husky, 1 Miniature Doberman, 1 Papillon, 1 Schnauzer,
1 Spitz, and 35 mongrels) were investigated in this study.
Of the 142 cases, 52.8% (75/142) were histologically
confirmed as carcinoma.
Analyzing the expression of KLF4 in paraffin-embedded
tissues by IHC revealed up-regulated nuclear KLF4 expres-
sion in mammary carcinomas as compared to benign
tumor cases (Table 1). We divided carcinoma patients into
three groups, either high KLF4 expression with Quick
score of 9-12, moderate KLF4 expression with Quick score
of 5-8, or weak KLF4 expression with Quick score of 1-4
(Figure 1). High expression of KLF4 (as defined by a
Quick score of 9 or greater) was identified in 59% (44/75)
of dogs with mammary carcinoma and none in the benign
tumors. Moreover, high expression level of KLF4 occurred
preferentially in the tumor cells and not the adjacent non-
tumor cells in mammary carcinoma (P < 0.001, Table 2
and Figure 2). Chi-square analyses for the clinicopatholo-
gic characteristics of the 75 canine mammary carcinoma
cases in relation to nuclear KLF4 expression showed that
high KLF4 expression correlated significantly with shorter
24-month survival (P = 0.01, Table 3). High KLF4 expres-
sion was also closely associated with poor grade, late stage,
and histological subtypes of simple and complex carci-
noma. The Kaplan-Meier survival curves indicated
that patients with high nuclear expression of KLF4 had a
significantly poor survival than those with low/moderate
KLF4 expression as defined by log-rank test (P = 0.011,
Figure 3).
Discussion
Studies of KLF proteins in mouse models of human dis-
eases have revealed the normal biological roles of the
KLFs as well as their involvement in the pathogenesis of a
variety of diseases such as cancer [20]. Previous studies
have shown that approximately 70% of human breast can-
cer has increased KLF4 expression and that up-regulated
nuclear KLF4 expression is associated with a more aggres-
sive phenotype [18,21]. The oncogenic properties of KLF4
in breast cancers was also confirmed in vitro and using
xenograft tumor model in which KLF4 knockdown inhib-
ited breast cancer development [22].
The breast cancer stem cell hypotheses suggest that
breast cancer is derived from a single cell with stem-like
properties that is capable of tumor initiation and forma-
tion. KLF4 can inhibit differentiation and increase self-
renewal in embryonic stem (ES) cells [23,24]. Forced
expression of KLF4, along with transcription factors,
Oct4, c-myc, and Sox2, can reprogram or dedifferentiate
somatic cells into
induced pluripotent stem cells (iPSCs) in both mice
[25,26] and human [27-29]. Taken together, these find-
ing suggest that KLF4 is indispensable for the regulation
of stem cells and contributes to tumorigenesis.
In this study, we investigated the expression and clinical
relevance of KLF4 in canine mammary carcinoma. Immu-
nihistochemistry revealed that nuclear expression of KLF4
was elevated in tumor cells of canine mammary carci-
noma. Although increased KLF4 expression was not
related to prognostic markers such as ER, PR or HER2.
High nuclear KLF4 expression was associated significantly
with a more aggressive phenotype as indicated by poor
grade, late stage, histological subtypes of simple and com-
plex carcinoma, and shorter 24-month survival in canine
mammary carcinoma. Despite diffuse cytoplasmic KLF4
expression with different degree of intensity was observed
among the samples. The cytoplasmic KLF4 expression was
not related to any clinicopathologic parameters and survi-
val (data not shown). The Kaplan-Meier survival analysis
also indicated that dogs with high nuclear expression of
KLF4 had a significantly shorter survival as compared with
ones with low/moderate nuclear KLF4 expression.
We provided evidence for the first time that KLF4 is
preferentially and highly expressed in canine mammary
carcinoma. As in human breast cancer, KLF4 plays an
oncogenic role in canine mammary carcinoma. Further
studies are needed to validate whether systemic targeting
of KLF4 would inhibits the oncogenic functions of KLF4
thus provides an effective strategy for the treatment of
canine mammary carcinoma.
Conclusions
Nuclear expression of KLF4 is frequently elevated in
canine mammary carcinoma and closely correlated with
a more aggressive phenotype and shorter survival.
Methods
KLF4 Immunohistochemistry
Paraffin-embedded tissue blocks of 142 cases of canine
mammary tumor diagnosed between January 2003 and
April 2008 were retrieved from the archives of the School
of Veterinary Medicine, National Taiwan University, Tai-
wan. The tumors were diagnosed according to the WHO
criteria for canine mammary neoplasms [30]. Samples
Table 1 Immunohistochemical quantitation of nuclear
KLF4 expression with the Quick score in canine
mammary tumor
Quick score
Histological classification 0 1-4 5-8 9-12 total
Benign tumor 0 60 7 0 67
Carcinoma 0 12 19 44 75
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graded alcohols, followed by a rinse using 10 mM Tris-
HCl (pH 7.4) and 150 mM sodium chloride, then treated
with 3% hydrogen peroxide for 5 min. Slides were incu-
bated with 1:250 dilution of anti-KLF4 antibody (sc-20691,
Santa Cruz Biotechnology, USA) for 1 hour at room tem-
perature, then thoroughly washed three times with PBS.
Bound antibodies were detected using the LSAB+ kit
(Dako, USA). The slides were then counterstained with
haematoxylin stain solution. Paraffin-embedded sections
of human breast cancer cells of homogeneous KLF4
i m m u n o p h e n o t y p ew e r ei n c l u d e da sp o s i t i v ec o n t r o l s .
Negative controls had the primary antibody omitted and
replaced by PBS. Quantification of KLF4 expression was
carried out using Quick score which multiply the staining
intensity by the percentage of positive cells [31-33]. The
intensity of staining was scored as 0, 1, 2, and 3 standing
for negative, weak, moderate, and strong staining, respec-
tively. The percentage of tumor cells staining positively
was scored as follows: 0 = 0%, 1 = 1-25%, 2 = 26-50%, 3 =
51-75%, and 4 = 76-100%, compared with the total of
tumor cells. The immunohistochemical results were evalu-
ated by two investigators scoring independently. Conflict-
ing scores were resolved at a dual head microscope.
Molecular Phenotyping
Immunohistochemistry was performed in parallel as
described above with monoclonal antibodies for ER
(1:35 dilution, Dako, Denmark), PR (1:200 dilution,
Thermo Scientific, USA), HER2 (1:400 dilution, Dako,
Denmark), CK5 (1:100 dilution, Novacastra, UK), and P-
cadherin (1:100 dilution, Novacastra, UK). ER and PR
immunoreactivity was considered positive when more
than 10% of the neoplastic cells expressed this marker
[5]. HercepTest scoring system was applied to evaluate
HER2 expression (0 = no staining or membrane staining
in fewer than 10% of tumor cells; 1+ = faint, barely per-
ceptible membrane staining in more than 10% of tumor
cells; 2+ = weak to moderate complete membrane stain-
ing observed in more than 10% of tumor cells; 3+ =
strong and complete membrane staining in more than
10% tumor cells) [5]. In this study, overexpression of
HER2 was defined as a HercepTest score of 3+. As for
CK5 and P-cadherin, cytoplasmic staining in > 50% of
cells was considered positive [5]. Immunohistochemical
panel which involved the evaluation of ER, HER2, CK5,
and P-cadherin was used to distinguish canine mam-
mary carcinoma subtypes [5,34].
Figure 1 Representative immunohistochemical staining patterns of KLF4 in canine mammary carcinoma (×400). (A) weak (B) moderate
(C) strong nuclear KLF4 expression.
Table 2 Expression of KLF4 in canine mammary tumor
Pathological diagnosis
KLF4 expression Benign tumor Carcinoma Total P
Tumor part
Quick score < 9 67(100%) 31(41.3%) 98 < 0.001
≧ 9 0 44(58.7%) 44
Non-tumor part
Quick score < 9 67(100%) 75(100%) 142 N/A
≧ 90 00
Figure 2 Elevated KLF4 expression identified in tumor cells
and not adjacent non-tumor cells in a representative canine
mammary carcinoma (40X).
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Page 3 of 6Table 3 Clinicopathologic characteristics of canine mammary carcinoma
KLF4 expression (Quick score)
low/moderate (< 9) High (≧ 9) N P
n% n %
Age
< 12 years 14 45.2% 17 38.6% 31 0.572
≧ 12 years 17 54.8% 27 61.4% 44
Ovariohysterectomy
No 26 83.9% 33 75.0% 59 0.356
Yes 5 16.1% 11 25.0% 16
Tumor Size
T1 (< 3 cm) 15 48.4% 11 25.0% 26
T2 (≧ 3 cm, < 5 cm) 7 22.6% 18 40.9% 25 0.089
T3 (> 5 cm) 9 29.0% 15 34.1% 24
Grade
I 12 38.7% 5 11.4% 17
II 14 45.2% 22 50.0% 36 0.009
III 5 16.1% 17 38.6% 22
Histological classification
Carcinoma in benign tumor 5 16.1% 0 0.0% 5
Complex carcinoma 14 45.2% 21 47.7% 35 0.020
Simple carcinoma 12 38.7% 23 52.3% 35
Location of affected gland
cranial 10 32.3% 17 38.6% 27 0.571
caudal 21 67.7% 27 61.4% 48
Stage
I 15 48.4% 5 11.4% 20
II 5 16.1% 13 29.5% 18
III 4 12.9% 7 15.9% 11 0.006
IV 4 12.9% 15 34.1% 19
V 3 9.7% 4 9.1% 7
ER
Negative 16 51.6% 23 52.3% 39 0.955
Positive 15 48.4% 21 47.7% 36
PR
Negative 6 19.4% 5 11.4% 11 0.509
Positive 25 80.6% 39 88.6% 64
Her-2/neu
Negative 26 83.9% 32 72.7% 58 0.281
Positive 5 16.1% 12 27.3% 17
Molecular phenotyping
Basal 10 32.3% 15 34.1% 25
HER-2 overexpressing 2 6.5% 5 11.4% 7
Luminal A 12 38.7% 14 31.8% 26 0.761
Luminal B 3 9.7% 7 15.9% 10
Null 4 12.9% 3 6.8% 7
Survival
a
< 24 months 9 56.3% 34 89.5% 43 0.010
≧ 24 months 7 43.8% 4 10.5% 11
a Twenty-one cases lacked survival data and were excluded from the analysis.
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Overexpression of KLF4 was defined as a Quick score of 9
or greater on the scale of 0 to 12. Patterns and correlations
of KLF4 and clinicopathologic parameters of canine mam-
mary tumor were examined by Pearson’s chi-square test.
Survival rate was calculated using Kaplan-Meier analysis
and compared by the Cochran-Mantel-Haenszel test (log-
rank test). Survival was defined as the time between date
of diagnosis and date of death. Subjects still alive at the
end of the study were censored at the date of last follow-
up. Cases that lacked survival information were excluded
from the analysis. A P value of less than 0.05 was consid-
ered to indicate statistical significance.
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